Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

61590 Press Releases
DateTitleCompany
30 May 15 SIRFLOX Study Presented at ASCO 2015 Annual Meeting Sirtex Medical Limited,
Published by
PR Newswire
30 May 15 Tokai Pharmaceuticals Announces Presentation at the 2015 ASCO Annual Meeting Tokai Pharmaceuticals,
Published by
Business Wire
30 May 15 Clovis Oncology’s Phase 2 Studies of Rucaparib in Ovarian Cancer Demonstrate Highly Compelling Clinical Activity in Both BRCA-mutant and BRCA-like Patients Together Comprising Approximately 60 Percent of Patients Clovis Oncology, Inc.,
Published by
Business Wire
30 May 15 ImmunoGen’s Mirvetuximab Soravtansine (IMGN853) Demonstrates Notable Single Agent Activity for Patients with Platinum-Resistant Ovarian Cancer ImmunoGen, Inc.,
Published by
Business Wire
30 May 15 Adaptimmune Announces Data From Clinical Studies of NY-ESO-1 Specific T-Cells in Multiple Cancers at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting Adaptimmune LLC,
Published by
GlobeNewswire
30 May 15 AstraZeneca and MedImmune Present Positive Immuno-Oncology Combination Data at ASCO 2015 AstraZeneca,
Published by
Business Wire
30 May 15 Kolltan Pharmaceuticals Announces Presentation of KTN3379 Interim Phase 1b Data at 2015 American Society of Clinical Oncology Annual Meeting Kolltan Pharmaceuticals, Inc.,
Published by
Business Wire
30 May 15 Acelarin® achieves very high disease control rates in patients with advanced gynaecological cancers in a Phase I/II setting NuCana,
Published by
Business Wire
30 May 15 Ground-breaking Final Results of the First in Human Phase I/II Study with Acelarin in Advanced Solid Tumours NuCana,
Published by
Business Wire
30 May 15 Pfizer Announces Palbociclib More Than Doubled Progression-Free Survival in Phase 3 Trial for Patients With HR+ HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy Pfizer Inc.,
Published by
Business Wire
30 May 15 Updated Positive Results from Two Trials of Cobimetinib in Combination with Vemurafenib for the Treatment of Patients with Advanced Melanoma Presented at 2015 ASCO Annual Meeting Exelixis Inc.,
Published by
Business Wire
30 May 15 Studies Presented at 2015 ASCO Meeting Demonstrate Predictive Power of bioTheranostics’ Breast Cancer Index? Molecular Test in Endocrine Therapy Decisions bioTheranostics, Inc.,
Published by
Business Wire
30 May 15 Updated Data Showed Genentech’s Investigational Combination of Cobimetinib and Zelboraf (Vemurafenib) Helps People With Advanced Melanoma Live for a Year Without Their Disease Worsening Genentech,
Published by
Business Wire
30 May 15 Genentech’s Gazyva® Extended the Time People With Refractory Indolent Non-Hodgkin’s Lymphoma Lived Without Their Disease Worsening Genentech,
Published by
Business Wire
30 May 15 Bellicum Announces ASCO Presentation Featuring its Novel CAR T Cell Co-Stimulatory Domain Designed to Improve Potency Against Solid Tumors Bellicum Pharmaceuticals, Inc.,
Published by
Business Wire
30 May 15 Information Update - Recall of "Galenic Health Ginger in Bentonite" due to unacceptable levels of lead for children and adolescents Health Canada,
Published by
PR Newswire
30 May 15 Sarepta Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Sarepta Therapeutics, Inc.,
Published by
Business Wire
29 May 15 Alexion and Synageva Announce Early Termination of Hart-Scott-Rodino Waiting Period for Alexion’s Pending Acquisition of Synageva Alexion Pharmaceuticals, Inc.,
Published by
Business Wire
29 May 15 BioMed Realty Trust Sells King of Prussia Property in Radnor to Penn Medicine for $35 Million BioMed Realty Trust, Inc.,
Published by
Business Wire
29 May 15 ArQule Announces Data Presentations with Tivantinib and ARQ 087 to Be Featured at ASCO 2015 ArQule, Inc.,
Published by
Business Wire
29 May 15 Saleem Musallam & Excite Medical Continue to Provide First Class Service & Support Excite Medical,
Published by
PR Newswire
29 May 15 Personal Genome Diagnostics Launches ImmunoSelect™-R For Identification Of Immunogenic Cancer Mutations To Support Immuno-Oncology Drug Development Personal Genome Diagnostics, Inc.,
Published by
PR Newswire
29 May 15 OPKO Announces Submission of Rayaldee™ New Drug Application to U.S. Food and Drug Administration OPKO Health, Inc.,
Published by
Business Wire
29 May 15 Dicerna to Present at the Jefferies 2015 Healthcare Conference Dicerna Pharmaceuticals, Inc.,
Published by
Business Wire
29 May 15 New Findings Show Durable Anti-Tumor Activity with KEYTRUDA® (pembrolizumab) Merck’s Anti-PD-1 Therapy in Patients with Advanced Head and Neck Cancer Regardless of PD-L1 Expression Status Merck,
Published by
Business Wire
29 May 15 Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers Squibb’s PD-1 Immune Checkpoint Inhibitor is First to Demonstrate Anti-Tumor Activity In Patients With Hepatocellular Carcinoma Bristol-Myers Squibb Company,
Published by
Business Wire
29 May 15 Opdivo (nivolumab) First PD-1 Inhibitor to Demonstrate Superior Overall Survival Versus Standard of Care (docetaxel) in Previously-Treated Non-Squamous Non-Small Cell Lung Cancer in Pivotal Phase III Trial Bristol-Myers Squibb Company,
Published by
Business Wire
29 May 15 BIO Thanks USDA for Commitment to Building Renewable Fuel Infrastructure Biotechnology Industry Organization (BIO),
Published by
Business Wire
29 May 15 Medisico plc: DELAY TO ACCOUNTS Medisico plc,
Published by
GlobeNewswire
29 May 15 Ovid Therapeutics to Present at Jefferies 2015 Global Healthcare Conference Ovid Therapeutics Inc.,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.